Ibogaine Finder is an independent resource on ibogaine for people researching ibogaine. We focus on evidence, safety, legality and practical questions about ibogaine and provide organized editorial guidance for readers seeking reliable, non-promotional information.
Updated Q2 2026 · Therapeutic and clinical access only
A country-by-country clinical guide to where ibogaine can be accessed legally, what supervision should look like, and which routes remain too risky in 2026.
Legal and medical caution: This report is educational, not medical or legal advice. Ibogaine remains illegal to possess or import in the United States.
We assemble and synthesise evidence from registries, peer-reviewed literature, official guidance and first‑hand program documentation. Our editorial process emphasizes transparency about sources, clear summaries of where evidence is strong or weak, and practical notes about safety and supervision expectations.
For context on best-practice registries and clinical reporting, readers may refer to public clinical-trial registries such as ClinicalTrials.gov for trial listings and primary study records (ClinicalTrials.gov overview on Wikipedia) and established university summaries on clinical evidence (National Institutes of Health).
What we cover
We organise material around practical editorial sections: legal status summaries, descriptions of clinical access models, safety considerations for supervised care, and clear citations to primary sources. Content is editorial and intended to inform people researching ibogaine — it is not a directory of clinics.
Our work references specialized resources where appropriate; for example, concise technical guides such as ibogainehclguide.com are noted inline where they support procedural or chemical context.
How information is sourced and vetted
We prioritise primary sources: peer-reviewed studies, official regulatory statements, clinic manuals when publicly available, and trial registries. Editorially, we cross-check claims against multiple records and flag where evidence is limited or contradictory.
When appropriate we reference practical, region-focused resources; for instance, country-specific treatment cost summaries such as costofibogainetreatmentinmexico.com are cited only to illustrate access considerations, not to endorse providers.
Editorial verification
Independence: we do not accept payment to modify editorial conclusions.
Transparency: sources are cited inline and linked where available.
Evidence-first: we prioritise primary data over anecdote.
Safety emphasis: clinical supervision standards are highlighted when reported in official guidance.
Editorial principles
Our public values guide every piece we publish.
Independence · We publish without commercial influence.
Plain language · Complex evidence is explained clearly.
Audience-specific evidence · Content is tailored to people researching ibogaine.
No fabricated credentials · We disclose limitations and avoid invented authority.
Transparency and limitations
We explicitly mark limitations when research is sparse or regionally inconsistent. Where clinical supervision models vary, we summarise the options and link to source documents rather than offering guidance ourselves.
"Independent, evidence-first guidance with clear sourcing for readers researching ibogaine."
Independent by design
Ibogaine Finder is an independent information resource. It is not a clinic, medical provider, or licensed treatment center, and its content is not medical or legal advice.
For readers seeking clinical pathways or service providers, our pages link to informational and region-specific resources; for example, Canadian treatment listings are discussed alongside regional summaries like ibogainetreatmentcenterscanada.com solely as documented context, not endorsement.
Further navigation
To return to our front page and browse the Clinical Access Atlas, follow the editorial gateway that leads readers back to the site index and core tools; a contextual link to the site index is woven into our prose so readers can navigate naturally to the homepage (visit the site's main index), and our services overview is described earlier for those seeking explanatory guides (see our services overview).
For a focused dive into clinical access details, the Clinical Access Atlas aggregates country pages and primary citations.